Molecular Partners AG ADR(MOLN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 5 at 4:00 PM ET (Korea 11/6 06:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.69 | Insider Own | 0.28% | Shs Outstand | 38.3M | Perf Week | -6.8% |
| Market Cap | 0.13B | Forward P/E | - | EPS next Y | 12.65% | Insider Trans | - | Shs Float | 38.2M | Perf Month | -13.65% |
| Enterprise Value | 0.06B | PEG | - | EPS next Q | -0.44 | Inst Own | 9.38% | Short Float | - | Perf Quarter | -18.77% |
| Income | -0.06B | P/S | - | EPS this Y | 18.93% | Inst Trans | 0.04% | Short Ratio | 0.3 | Perf Half Y | -19.76% |
| Sales | 0.00B | P/B | 2.08 | EPS next 5Y | 9.82% | ROA | -58.81% | Short Interest | 0.00M | Perf YTD | -24.52% |
| Book/sh | 1.58 | P/C | 1.83 | EPS past 3/5Y | - 5.73% | ROE | -71.01% | 52W High | -38.62% ($5.36) | Perf Year | -18.29% |
| Cash/sh | 1.8 | P/FCF | - | Sales past 3/5Y | - | ROIC | -102.66% | 52W Low | 6.47% ($3.09) | Perf 3Y | -28.79% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 11.22% | Gross Margin | - | Volatility(W/M) | 3.37% 3.55% | Perf 5Y | -81.48% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 0.2 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 6.46 | EPS Q/Q | 4.91% | Profit Margin | - | RSI (14) | 38.28 | Recom | 1.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.46 | Sales Q/Q | - | SMA20 | -8.63% ($3.6) | Beta | 1.14 | Target Price | $11.13 |
| Payout | - | Debt/Eq | 0.05 | Earnings | 2026/10/29 | SMA50 | -16.9% ($3.96) | Rel Volume | 2.44 | Prev Close | $3.25 |
| Employees | 149 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | - | SMA200 | -20.89% ($4.16) | Avg Volume(3M) | 0.00M | Price | $3.29 |
| IPO | 2021/6/16 | Option/Short | No/Yes | Trades | 51 | Volume | 4,790 | Change | 1.33% |
🧬 A clinical-stage biotechnology company headquartered in Zurich, Switzerland, developing novel drug candidates in oncology and infectious diseases based on its proprietary protein therapeutics platform known as DARPins (DARPin). The company continues to expand its pipeline through joint research and technology transfer collaborations with multinational pharmaceutical companies. It is a stock that combines the high growth potential characteristic of clinical-stage biotechs with the corresponding volatility.
Over the past 1 year, on the lower side
39% below its 1-year high.
Traded more than usual. That is 244% of its average volume.
MOLN has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +18.9% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -81.5%. The S&P 500 did +56% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 9.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
AVDE Avantis International Equity ETF <0.01% It ranks #330 of 597 in the industry
Based on market cap of $126M.
YARW#329 Yarrow Bioscience Inc $128M PER - MOLN#330 Molecular Partners AG ADR $126M PER - 
TARA#331 Protara Therapeutics Inc $126M PER - 
CMPX#332 Compass Therapeutics Inc $123M PER - 
PDSB#333 PDS Biotechnology Corp $123M PER - 
FAQ
What kind of company is MOLN?
MOLN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MOLN?
The market cap of MOLN is approximately $126M, ranking 4,332 within its sector.
What is the 52-week high and low for MOLN?
MOLN has recorded a 52-week high of $5.36 and a low of $3.09.
